Fig. 7. The effect of BRG1 expression on the protein levels of Rho-kinase/ROCK proteins. Immunfluorescence images of BRG1-expressing cells exposed to the Rho-kinase/ROCK inhibitor Y-27632 for 1 hour, fixed and stained with FITC-phalloidin (A) and native SW13 cells exposed to the same treatment as BRG1-expressing cells (B). Bar, 20 µm. (C) Immunoblots of cell lysate (20 µg/sample) of SW13 cells transfected with the pBJ5-BRG1 or the pBJ5-BRG1-K798R expression vector. Samples were taken at the time points indicated above the lanes. The membranes were probed with a C-terminal antiserum against BRG1, ROCK1 antibodies, ROCK2 antibodies, a Dia1 antiserum, ß-actin antibodies and -tubulin antibodies as indicated on the left. The BRG1-transfection is shown on the left and the BRG1-K798R on the right as indicated (representative of one experiment of five). (D) Immunoblots of the level of ROCK1, ROCK2, Dia1, RhoA, HDAC2, P65 of NFB and -tubulin in cell lysate (20 µg/lane) of BRG1-expressing cells (labelled `0'), cells that were transfected with a 5 µg GFP-expressing vector (labelled `V') or a GFP-expressing vector co-expressing a specific antisense BRG1-fragment. The amount of GFP-BRG1-antisense vector used is given above the lanes.